Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550519 | 0.84 | CDC25A (0.49) | RECQLNPY5RALDH1A1NPSR1KMT2A | |
| SCHEMBL2399858 | 0.76 | ALDH1A1 (0.40) | RECQLNPY5RALDH1A1NPSR1POLB | |
| SCHEMBL3549221 | 0.74 | KMT2A (0.40) | ALDH1A1NPSR1KMT2APOLB | |
| SCHEMBL2400338 | 0.73 | CDC25A (0.44) | NPY5RALDH1A1NPSR1KMT2APOLB | |
| SCHEMBL3552597 | 0.73 | ALDH1A1 (0.39) | NPY5RALDH1A1NPSR1KMT2A | |
| SCHEMBL3550580 | 0.70 | ALDH1A1 (0.39) | ALDH1A1NPSR1LMNA | |
| SCHEMBL2399861 | 0.70 | ALDH1A1 (0.40) | ALDH1A1NPSR1KMT2APOLB | |
| SCHEMBL3547560 | 0.69 | KDM4E (0.45) | NPY5RALDH1A1NPSR1KMT2APOLB | |
| SCHEMBL3547580 | 0.69 | ALDH1A1 (0.45) | ALDH1A1NPSR1KMT2ALMNAGLA | |
| SCHEMBL1917793 | 0.69 | CDC25A (0.60) | RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2010-12-16 | — | — | US | claimed |
| US-7795284-B2 | 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses | IPSEN PHARMA S.A.S. (FR) | 2010-09-14 | — | — | US | claimed |
| EP-1814879-B1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOD CONSEILS RECH APPLIC (FR) | 2008-09-24 | — | — | EP | claimed |
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2007-10-18 | — | — | US | claimed |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2010-12-16 | — | — | US | disclosed |
| US-7795284-B2 | 4,7-dioxobenzothiazole-2-carboxamide derivatives, their preparation and their therapeutic uses | IPSEN PHARMA S.A.S. (FR) | 2010-09-14 | — | — | US | disclosed |
| EP-1814879-B1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOD CONSEILS RECH APPLIC (FR) | 2008-09-24 | — | — | EP | disclosed |
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | IPSEN PHARMA S.A.S. (FR) | 2007-10-18 | — | — | US | disclosed |
| EP-1814879-A1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S) SAS (FR) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051202-A1 | DERIVATIVES OF 4,7-DIOXOBENZOTHIAZOLE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND THERAPEUTIC USES OF SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) SAS (FR) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244186-A1 | 4, 7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation and Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | RECQL 978/4885NPY5R 2634/4885ALDH1A1 2011/4885 |
| US-20100317658-A1 | 4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses | CDC25C, CDC25A, CDC25B | RECQL 978/4885NPY5R 2634/4885ALDH1A1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.